Steven G Nadler

List of Publications by Year
in descending order

51 papers	2,551 citations	186265 28 h-index	189892 50 g-index
51 all docs	51 docs citations	51 times ranked	3231 citing authors

#	Article	IF	Citations
1	Discovery of a JAK1/3 Inhibitor and Use of a Prodrug To Demonstrate Efficacy in a Model of Rheumatoid Arthritis. ACS Medicinal Chemistry Letters, 2019, 10, 306-311.	2.8	11
2	Development of a Molecular Signature to Monitor Pharmacodynamic Responses Mediated by In Vivo Administration of Glucocorticoids. Arthritis and Rheumatology, 2018, 70, 1331-1342.	5.6	15
3	Renal Cell Carcinoma (RCC) Tumors Display Large Expansion of Double Positive (DP) CD4+CD8+ T Cells With Expression of Exhaustion Markers. Frontiers in Immunology, 2018, 9, 2728.	4.8	39
4	Circulating T Cell Subpopulations Correlate With Immune Responses at the Tumor Site and Clinical Response to PD1 Inhibition in Non-Small Cell Lung Cancer. Frontiers in Immunology, 2018, 9, 1613.	4.8	83
5	Discovery of potent and efficacious pyrrolopyridazines as dual JAK1/3 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 3101-3106.	2.2	10
6	A Systemic Lupus Erythematosus Endophenotype Characterized by Increased CD8 Cytotoxic Signature Associates with Renal Involvement. ImmunoHorizons, 2017, 1, 124-132.	1.8	11
7	Abatacept Inhibition of T Cell Priming in Mice by Induction of a Unique Transcriptional Profile That Reduces Their Ability to Activate Antigenâ€Presenting Cells. Arthritis and Rheumatology, 2016, 68, 627-638.	5.6	23
8	Functional Antagonism of Human CD40 Achieved by Targeting a Unique Species-Specific Epitope. Journal of Molecular Biology, 2016, 428, 2860-2879.	4.2	13
9	Integrated Pharmacokinetic/Pharmacodynamic Analysis for Determining the Minimal Anticipated Biological Effect Level of a Novel Anti-CD28 Receptor Antagonist BMS-931699. Journal of Pharmacology and Experimental Therapeutics, 2015, 355, 506-515.	2.5	17
10	Improving the Pharmacokinetic and CYP Inhibition Profiles of Azaxanthene-Based Glucocorticoid Receptor Modulatorsâ€"Identification of (S)-5-(2-(9-Fluoro-2-(4-(2-hydroxypropan-2-yl)phenyl)-5H-chromeno[2,3-b]pyridin-5-yl)-2-methylpropanamido)-N-(tetrahydro-2H-pyran-4-y (BMS-341). Journal of Medicinal Chemistry, 2015, 58, 4278-4290.	6.4	15
11	Discovery of pyrrolo[1,2-b]pyridazine-3-carboxamides as Janus kinase (JAK) inhibitors. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 5721-5726.	2.2	27
12	Discovery of acylurea isosteres of 2-acylaminothiadiazole in the azaxanthene series of glucocorticoid receptor agonists. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 3268-3273.	2.2	11
13	Heterocyclic glucocorticoid receptor modulators with a 2,2-dimethyl-3-phenyl-N-(thiazol or) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T	2.2	7
14	Discovery of potent and selective nonsteroidal indazolyl amide glucocorticoid receptor agonists. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 5442-5447.	2.2	14
15	Synthesis and structureâ€"activity relationships of novel indazolyl glucocorticoid receptor partial agonists. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 5448-5451.	2.2	11
16	Advances in CTLA-4-Ig-mediated modulation of inflammatory cell and immune response activation in rheumatoid arthritis. Autoimmunity Reviews, 2013, 12, 758-767.	5.8	77
17	A Monovalent Anti-Human CD28 Domain Antibody Antagonist: Preclinical Efficacy and Safety. Journal of Immunology, 2013, 191, 4599-4610.	0.8	49
18	Azaxanthene Based Selective Glucocorticoid Receptor Modulators: Design, Synthesis, and Pharmacological Evaluation of (S)-4-(5-(1-((1,3,4-Thiadiazol-2-yl)amino)-2-methyl-1-oxopropan-2-yl)-5H-chromeno[2,3-b]pyridin-2-yl)-2-fluoro-N (BMS-776532) and Its Methylene Homologue (BMS-791826). Journal of Medicinal Chemistry, 2011, 54, 7318-7333.	6.4	56

#	Article	IF	Citations
19	Dimethyl-diphenyl-propanamide Derivatives As Nonsteroidal Dissociated Glucocorticoid Receptor Agonists. Journal of Medicinal Chemistry, 2010, 53, 8241-8251.	6.4	34
20	Targeting lymphocyte co-stimulation: From bench to bedside. Autoimmunity, 2010, 43, 514-525.	2.6	33
21	Abatacept Limits Breach of Self-Tolerance in a Murine Model of Arthritis via Effects on the Generation of T Follicular Helper Cells. Journal of Immunology, 2010, 185, 1558-1567.	0.8	88
22	Novel Synthesis of the Hexahydroimidazo[1,5b]isoquinoline Scaffold: Application to the Synthesis of Glucocorticoid Receptor Modulators. Journal of Medicinal Chemistry, 2010, 53, 1270-1280.	6.4	29
23	Costimulation Modulation Uncouples Protection from Immunopathology in Memory T Cell Responses to Influenza Virus. Journal of Immunology, 2009, 182, 6834-6843.	0.8	54
24	Surface CD152 (CTLA-4) Expression and Signaling Dictates Longevity of CD28null T Cells. Journal of Immunology, 2009, 182, 5342-5351.	0.8	21
25	Abatacept Does Not Induce Direct Gene Expression Changes in Antigen-Presenting Cells. Journal of Clinical Immunology, 2009, 29, 479-489.	3.8	19
26	The clinical utility of inhibiting CD28â€mediated costimulation. Immunological Reviews, 2009, 229, 307-321.	6.0	148
27	Discovery of novel dihydro-9,10-ethano-anthracene carboxamides as glucocorticoid receptor modulators. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 2139-2143.	2.2	20
28	Identification of potent pyrimidine inhibitors of phosphodiesterase 7 (PDE7) and their ability to inhibit T cell proliferation. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 1935-1938.	2.2	20
29	Abatacept modulates human dendritic cell-stimulated T-cell proliferation and effector function independent of IDO induction. Clinical Immunology, 2008, 126, 38-47.	3.2	62
30	CTLA4 Expression Is an Indicator and Regulator of Steady-State CD4+FoxP3+ T Cell Homeostasis. Journal of Immunology, 2008, 181, 1806-1813.	0.8	103
31	Abatacept binds to the Fc receptor CD64 but does not mediate complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity. Journal of Rheumatology, 2007, 34, 2204-10.	2.0	86
32	Control of Memory CD4 T Cell Recall by the CD28/B7 Costimulatory Pathway. Journal of Immunology, 2006, 177, 7698-7706.	0.8	124
33	An intracellular targeted NLS peptide inhibitor of karyopherin Î±:NF-ÎºB interactions. Biochemical and Biophysical Research Communications, 2003, 300, 403-407.	2.1	25
34	Phosphodiesterase 7A-Deficient Mice Have Functional T Cells. Journal of Immunology, 2003, 171, 6414-6420.	0.8	95
35	In vivo administration of 15-deoxyspergulin inhibits antigen-presenting cell stimulation of T cells and NF-ÎºB activation. International Immunopharmacology, 2002, 2, 1451-1464.	3.8	10
36	Role of NF-ÎºB in Endotoxemia-Induced Alterations of Lung Neutrophil Apoptosis. Journal of Immunology, 2001, 167, 7044-7051.	0.8	47

#	Article	IF	Citations
37	Nuclear localization of the tyrosine kinase Itk and interaction of its SH3 domain with karyopherin Î± (Rch1Î±). International Immunology, 2001, 13, 1265-1274.	4.0	28
38	A<scp>d</scp>-Amino Acid Peptide Inhibitor of NF-ÎºB Nuclear Localization Is Efficacious in Models of Inflammatory Disease. Journal of Immunology, 2000, 165, 1004-1012.	0.8	54
39	Two nuclear localization signals in the HIV-1 matrix protein regulate nuclear import of the HIV-1 pre-integration complex 1 1Edited by M. Gottesman. Journal of Molecular Biology, 2000, 299, 359-368.	4.2	135
40	Reduced Levels of Hsp70 Result in a Therapeutic Effect of l5-Deoxyspergualin on Acute Graft-Versus-Host Disease in (DAÃ—LEW)Fl Rats. Immunobiology, 2000, 202, 254-266.	1.9	15
41	Modulation of Nuclear Protein Import. Biochemical Pharmacology, 1998, 56, 157-161.	4.4	18
42	Identification of a Binding Site on Hsc70 for the Immunosuppressant 15-Deoxyspergualin. Biochemical and Biophysical Research Communications, 1998, 253, 176-180.	2.1	65
43	CNI-H0294, a Nuclear Importation Inhibitor of the Human Immunodeficiency Virus Type 1 Genome, Abrogates Virus Replication in Infected Activated Peripheral Blood Mononuclear Cells. Antimicrobial Agents and Chemotherapy, 1998, 42, 1133-1138.	3.2	22
44	Differential Expression and Sequence-specific Interaction of Karyopherin Î± with Nuclear Localization Sequences. Journal of Biological Chemistry, 1997, 272, 4310-4315.	3.4	160
45	Role of Oxidative Stress in the Action of Vanadium Phosphotyrosine Phosphatase Inhibitors. Journal of Biological Chemistry, 1997, 272, 11541-11549.	3.4	127
46	15-deoxyspergualin: Immunotherapy in solid organ and cellular transplantation. Transplantation Reviews, 1996, 10, 160-174.	2.9	21
47	Binding Stoichiometry of the Cytotoxic T Lymphocyte-associated Molecule-4 (CTLA-4). Journal of Biological Chemistry, 1995, 270, 15417-15424.	3.4	91
48	Quantitation of the Interaction of the Immunosuppressant Deoxyspergualin and Analogs with Hsc70 and Hsp90. Biochemistry, 1994, 33, 2561-2567.	2.5	121
49	Identification and characterization of an NADPH-cytochrome P450 reductase derived peptide involved in binding to cytochrome P450. Archives of Biochemistry and Biophysics, 1991, 290, 277-284.	3.0	60
50	Cytochrome P-450: Cytochrome P-450 Reductase Interactions. Drug Metabolism Reviews, 1989, 20, 519-533.	3.6	37
51	Role of electrostatic interactions in the reaction of NADPH-cytochrome P-450 reductase with cytochromes P-450. Archives of Biochemistry and Biophysics, 1988, 261, 418-429.	3.0	90